MedTrace Logo

A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer

NCT05824247 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-04-21

No results posted yet for this study

Summary

A study to discuss the advantage of Fapi PET- CT in the initial diagnosis staging and lesion determination of ovarian cancer,whether it can be a evaluation strategy as an R0 evaluation tool or a prediction tool of chemotherapy response and evaluation of prognosis.

Conditions

Interventions

DEVICE

68Ga-FAPI-PET-CT

a new technology that using Fibroblast activation protein （FAP）inhibitor as the tracer of PET-CT

Sponsors & Collaborators

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2025-04-01
Completion
2025-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05824247 on ClinicalTrials.gov